EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

32. What should a board-ready GLP-1 procurement decision contain?

Dose Diligence research deskSection 01 · Page 32 of 34Last updated 17 Nov 2026

Present an evidenced route decision, a matched economic comparison and an executable continuity plan. Keep unresolved eligibility and quality questions outside the weighted commercial score.

Recommended approval pack:

  1. Decision: exact arrangement, products, facilities and patient population.
  2. Control of spending: clinic costs separated from patient and insurer expenditure.
  3. Eligibility: dated clinical, legal and state-permission review.
  4. Quality: evidence register, findings and unresolved requests.
  5. Economics: matched scenarios, ongoing prices and sensitivities.
  6. Operations: pilot results, responsibilities and service definitions.
  7. Resilience: dependencies, tested alternatives and transition plan.
  8. Contract exposure: minimums, deposits, remedies and exit costs.
  9. Monitoring: named owners and reconsideration triggers.

What should the team do over the next 30 days?

  • Week 1: map current arrangements, payment flows and failure data.
  • Week 2: issue one standardized evidence request and quotation template.
  • Week 3: complete specialist review and test shortlisted workflows.
  • Week 4: reconcile the cost model, negotiate protections and approve only the supported scope.

Immediate stop conditions: unidentified performing entity, unresolved product identity, unsupported route justification, material unaddressed quality concern or inability to reconcile patient orders.

The objective is not the cheapest advertised medicine. It is a defensible arrangement whose costs, responsibilities and failure modes the clinic understands.

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →